Lauren Buchanan, MA, Managing Editor

Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.

Audrey Dean’s case highlights the significance of tailoring treatments to individual patient needs, acknowledging that what works for one person might not work for another.

From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.

Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.

Grants allow investigators to uncover the potential causes and key aspects of rosacea to pave the way for improved treatment, prevention, and possibly a cure.

Susan C. Taylor, MD, FAAD, and George Han, MD, PhD, share insights on vitiligo awareness, demographics, treatment approaches, and the impact of the condition on patients’ quality of life.

The case of a 45-year-old woman with AD challenges clinicians on how to consider stress as an exacerbating factor in a treatment-resistant case.

New lifestyle transitions can affect a patient's treatment adherence and support network. How would you help this new college student?

Vilobelimab has received Fast Track and Orphan Drug designations from the FDA, as well as an Orphan Drug designation from the European Medicines Agency for the treatment of PG.

Investigators report 12 weeks of treatment provided a strong foundation for further evaluation of TAK-279 across the psoriatic arthritis disease spectrum.

Test your knowledge on approved biologics in the management of moderate to severe atopic dermatitis and considerations for an 18-year-old man's case.

Polyphenols, found in certain foods, have antioxidant and anti-inflammatory properties may help modulate immune responses, offering potential adjunctive therapy for atopic dermatitis, psoriasis, and chronic urticaria.

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Secukinumab is currently the only IL-17A inhibitor approved for the condition.

From reducing age spots to nurturing the lip microbiome and supporting sensitive skin, 3 studies presented at the 2023 Integrative Dermatology Symposium highlighted the transformative potential of botanicals in skincare.

A new AI platform empowers health care practitioners in numerous specialties to make informed decisions and provide high-quality care to patients with scabies.

The study encompassed an impressive 151 publications, comprising 110 studies and a total of 10,187 patients.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Sandra Lee, MD, and other top acne experts took the stage to debate cases and treatments.

The latest CDC data shows an uptick in syphilis, which can lead to a rare form of alopecia or a presentation of psoriasis.

Although still in its early stages, the program showcases the potential value of tangible interactions between dedicated navigators and patients in enhancing support and continuity of care.

The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.

The positive outcomes observed in these cases underscore the potential for these products to revolutionize the way dermatology clinicians address visible signs of facial aging.

Dawn Merritt, DO, and Mark Lebwohl, MD, took the stage to explain the history of CSU, the prevalence of testing and food avoidance, approved treatments, and monitoring treatment improvement for the condition.

April Armstrong, MD, MPH, and Peter Lio, MD, explained the science behind how AD impacts quality of life and biologics on the market to enhance treatment plans.

Test your knowledge on the foundation leading to the development of biologics to treat atopic dermatitis.

Cheryl Burgess, MD, will share pearls on counseling patients on appropriate cosmetic procedures for their skin type, safety measures, and strategies to achieve desired outcomes.

Looking to explore the city between Fall Clinical sessions or to extend your stay? Check out this top 10 list of the best Las Vegas has to offer in October.

One of the largest dermatology meetings of the year kicks off today with an exciting line up of expert perspectives and clinical pearls. Here's what you can expect.